CD160 Antibody (275) [Janelia Fluor® 549]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-90074JF549

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Applications

Flow Cytometry

Label

Janelia Fluor 549

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 275

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all CD160 Antibodies »

Product Summary for CD160 Antibody (275) [Janelia Fluor® 549]

Immunogen

This antibody was obtained from a rabbit immunized with purified, recombinant Human CD160 (Accession#: NP_008984.1; Met1-Leu158).

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Applications for CD160 Antibody (275) [Janelia Fluor® 549]

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: CD160

CD160, also known as BY55 and NK1, belongs to a class of natural killer (NK) receptors known as the major histocompatibility complex (MCH) class I-dependent NK cell activating receptor (1). CD160 exists as either a glycosylphosphatidylinositol (GPI)-anchored isoform or a transmembrane protein and is expressed on NK cells and cytotoxic T lymphocytes, as well as endothelial cells (1-3). CD160 has both stimulatory and inhibitory receptor functions and regulates cell differentiation and activation (2). The human CD160 protein is 181 amino acids (aa) in length with a theoretical molecular weight (MW) of 19.8 kDa (2,3). However, given that the CD160 protein is subject to glycosylation, addition of disulfide bonds, lipidation, and propitiation, the observed MW is often much higher (2). The human CD160 protein consists of a single immunoglobulin (Ig)-like domain (25-133 aa) and does not contain any immunoreceptor tyrosine-based activation motifs (ITSMs) (2). Thus, CD160 requires the recruitment of adaptor proteins such as phosphoinositide-3 kinase (PI3K) to promote cytotoxic functions including cytokine secretion (1,3).

Identified ligands for CD160 include MHC class I proteins and herpes virus entry mediators (HVEM), each of which has a different effect on NK or T cells (1,3-5). CD160 binds to MHC class I proteins with weaker affinity, but the interaction causes NK cell cytotoxic function and cytokine production (1,3). CD160 engagement of MHC class I proteins and/or HVEM within NK cells promotes ERK1/2 and AKT activation and production of interferon gamma (IFNgamma) (5). Conversely, CD160 binding of HVEM in CD4+ T cells induces inhibitory signaling, signifying both a stimulatory and inhibitory role for CD160 as well as cell-specific context (4,5). Additionally, CD160 plays a role in diseases including certain types of cancer, such as thyroid cancer and colon cancer, viral infections, and autoimmune diseases (3,5). CD160 expression levels on CD8+ T cells have been shown to be elevated in chronic viral infections such as human immunodeficiency virus (HIV) and Epstein Barr virus (EBV) (3). In addition, when CD160 is co-expressed with the programmed cell death protein 1 (PD-1) receptor, T cell exhaustion occurs due to persistent stimulation, leading to inhibited immune response and ability to combat infection (3). CD160 may be a promising therapeutic target in cancer as murine studies have demonstrated that blocking the CD160-HVEM pathway causes a regression of neoplastic tumors in a thyroid cancer model (3-5).

References

1. Le Bouteiller P, Tabiasco J, Polgar B, et al. CD160: a unique activating NK cell receptor. Immunol Lett. 2011;138(2):93-96. https://doi.org/10.1016/j.imlet.2011.02.003

2. Uniprotkb (O95971)

3. Piotrowska M, Spodzieja M, Kuncewicz K, Rodziewicz-Motowidlo S, Orlikowska M. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions. Eur J Med Chem. 2021;224:113694. https://doi.org/10.1016/j.ejmech.2021.113694

4. Cai G, Freeman GJ. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev. 2009;229(1):244-258. https://doi.org/10.1111/j.1600-065X.2009.00783.x

5. Sedy JR, Ramezani-Rad P. HVEM network signaling in cancer. Adv Cancer Res. 2019;142:145-186. https://doi.org/10.1016/bs.acr.2019.01.004

Alternate Names

BY55, CD160, NK1, NK28

Gene Symbol

CD160

Additional CD160 Products

Product Documents for CD160 Antibody (275) [Janelia Fluor® 549]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD160 Antibody (275) [Janelia Fluor® 549]

Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.